Plus Therapeutics Inc SEC Filings

PLUS THERAPEUTICS, Inc. (PSTV) reported an equity award to Marc H. Hedrick, its Chief Executive Officer and a director. On 08/13/2025 he was granted stock options to purchase 5,748,506 shares with an exercise price of $0.5744 and an expiration date of 08/12/2035, and 1,916,168 restricted stock units that convert one-for-one into common stock upon vesting. The option grant vests monthly over four years in equal 1/48th installments. The RSUs vest over three years with one-third vesting on the first anniversary and the remaining two-thirds vesting monthly over the following two years.

Richard J. Hawkins, a director of Plus Therapeutics, Inc. (PSTV), reported receipt of a stock option grant on 08/13/2025. The award is a stock option with an exercise price of $0.5744 covering 397,794 underlying shares. Following the reported transaction, the reporting person beneficially owns 397,794 shares on a direct basis. The option vests monthly over 12 months from the grant date and will vest in full at the issuer's 2026 annual stockholder meeting, subject to continued service. The option has an expiration date shown as 08/12/2035. The Form 4 was signed by an attorney-in-fact, Andrew Sims, on 08/15/2025.

PLUS THERAPEUTICS, Inc. (PSTV) director Howard Clowes was reported as the recipient of a stock option grant. The Form 4 shows a grant of 297,794 stock options at an exercise price of $0.5744, with a transaction date of 08/13/2025.

The options vest monthly over 12 months from the grant date, and vest in full at the issuer's 2026 Annual Stockholder Meeting, subject to continued service. Following the reported transaction, the reporting person beneficially owns 297,794 shares/options on a direct basis.

Robert P. Lenk, a director of PLUS THERAPEUTICS, Inc. (PSTV), was granted stock options on 08/13/2025. The Form 4 reports acquisition of 297,794 stock options with an exercise price of $0.5744 per share. The filing states the options vest monthly over 12 months from the grant date and vest in full upon the issuer's 2026 Annual Stockholder Meeting, subject to continued service. The Form 4 shows the reporting person holds 297,794 underlying shares following the transaction and is filed by one reporting person. The filing is signed by an attorney-in-fact on behalf of the reporting person.

Andrew John Hugh MacIntyre Sims, serving as Chief Financial Officer of PLUS THERAPEUTICS, Inc. (PSTV), reported equity awards granted on 08/13/2025. He received a stock option to purchase 1,379,636 shares at an exercise price of $0.5744 per share, exercisable through 08/12/2035, with the option vesting over four years in equal monthly 1/48th installments. He also received 459,878 restricted stock units (RSUs) that convert one-for-one into common stock upon vesting; the RSUs vest over three years with one-third vesting on the first anniversary and the remaining two-thirds vesting monthly over the next two years. The Form 4 was signed on 08/15/2025 and reports these grants as direct beneficial ownership following the transactions.

Reporting person: An van Es-Johansson, identified as a Director of PLUS THERAPEUTICS, Inc. (PSTV). Transaction: on 08/13/2025 the reporting person was granted 297,794 stock options with an exercise price of $0.5744. The options vest monthly over 12 months from the grant date in substantially equal installments and vest in full at the issuer's 2026 annual stockholder meeting if the reporting person remains in service. The options expire on 08/12/2035 and the report shows 297,794 underlying common shares beneficially owned following the transaction in a direct ownership form. The Form 4 was signed by an attorney-in-fact.

Plus Therapeutics, Inc. Schedule 13G/A filed by S.H.N. Financial Investments Ltd. reports beneficial ownership of 1,500,000 shares of common stock, representing 1.51% of the class based on 99,264,526 shares outstanding. The amendment references a prior Schedule 13G filed March 18, 2025, which covered 1,209,754 shares purchased March 4, 2025, indicating the reporter increased its position to the 1.5 million share level.

The filer is S.H.N. Financial Investments Ltd., organized in Israel, with Nir Shamir identified as CEO of the reporting entity and noted as potentially deemed to beneficially own the reported shares, though he disclaims ownership for other purposes. The filing certifies the shares were not acquired to influence control of the issuer.

Plus Therapeutics reported that Nasdaq's Listing Qualifications Department found it did not meet the minimum stockholders' equity requirement after the company reported a stockholders' deficit of ($23,641,000) for the period ended March 31, 2025. The Staff initially determined to delist the company's securities, and the company timely requested a hearing.

A Nasdaq Hearings Panel granted continued listing subject to two conditions: demonstrate compliance with the $2.5 million equity requirement by August 14, 2025 through a public filing describing transactions and indicating post-transaction equity (optionally including a balance sheet not older than 60 days with pro forma adjustments), and have the closing bid price meet or exceed $1.00 per share for 10 consecutive business days by September 8, 2025.